Nicholas J. Toms
University of Bristol
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Nicholas J. Toms.
British Journal of Pharmacology | 1996
Nicholas J. Toms; David E. Jane; Martyn C. Kemp; Jennifer S. Bedingfield; Peter J. Roberts
1 In this study we describe the potent antagonist activity of a novel metabotropic glutamate (mGlu) receptor antagonist (RS)‐α‐cyclopropyl‐4‐phosphonophenylglycine ((RS)‐CPPG) which exhibits selectivity for mGlu receptors (group II and III) negatively coupled to adenylyl cyclase in the adult rat cortex. 2 Both the L‐2‐amino‐4‐phosphonobutyrate (L‐AP4) and (2S, 1′S, 2′S)‐2‐(carboxycyclopropyl)glycine (L‐CCG‐1) inhibition of forskolin‐stimulated cyclic AMP accumulation were potently reversed by (RS)‐CPPG (IC50 values: 2.2 ± 0.6 nM and 46.2 ± 18.2 nM, respectively). 3 In contrast, (RS)‐CPPG acted as a weak antagonist against group I mGlu receptors. In neonatal rat cortical slices, (RS)‐CPPG antagonized (KB = 0.65 ± 0.07 mM) (1S, 3R)‐1‐aminocyclopentane‐1, 3‐dicarboxylic acid ((1S, 3R)‐ACPD)‐stimulated phosphoinositide hydrolysis. (RS)‐CPPG (100 μm) failed to influence L‐quisqualate‐stimulated phosphoinositide hydrolysis in cultured cerebellar granule cells. 4 In the rat cerebral cortex, (RS)‐CPPG is the most potent antagonist of group II/III mGlu receptors yet described (with 20 fold selectivity for group III mGlu receptors), having negligible activity at group I mGlu receptors.
Neuropharmacology | 1997
Nicholas J. Toms; M.E. Reid; W. Phillips; M.C. Kemp; Peter J. Roberts
Since kainate evokes large non-desensitizing currents at alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, kainate is of limited use in discriminating between AMPA and kainate receptors. Following recent reports that (2S,4R)-4-methylglutamate is a kainate receptor-selective agonist, we have radiolabelled and subsequently characterized the binding of [3H]-(2S,4R)-4-methylglutamate to rabbit whole-brain membranes. [3H]-(2S,4R)-4-methylglutamate binding was rapid, reversible and labelled two sites (KD1 = 3.67+/-0.50 nM/Bmax1 = 0.54+/-0.03 pmol/mg protein and KD2 = 281.66+/-12.33 nM/ Bmax2 = 1.77+/-0.09 pmol/mg protein). [3H]-(2S,4R)-4-methylglutamate binding was displaced by several non-NMDA receptor ligands: domoate > kainate >> L-quisqualate > or = L-glutamate > 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) >> (S)-AMPA = (S)-5-fluorowillardiine > NMDA. Neither the metabotropic glutamate receptor agonists (1S,3R)-ACPD or L-AP4, together with the L-glutamate uptake inhibitor L-trans-2,4-PDC, influenced binding when tested at 100 microM. We conclude that [3H]-(2S,4R)-4-methylglutamate is a useful radioligand for labelling kainate receptors. It possesses high selectivity, and possesses a pharmacology similar to that for rat cloned low-affinity (Glu5 and 6) kainate receptor subunits.
British Journal of Pharmacology | 1995
Nicholas J. Toms; D. E. Jane; H. W. Tse; Peter J. Roberts
1 The pharmacology of excitatory amino acid (EAA)‐stimulated phosphoinositide (PI) hydrolysis, monitored via [3H]‐inositol monophosphate accumulation, was investigated in primary cultures of rat cerebellar granule cells. 2 EAA‐stimulated PI hydrolysis peaked after 4–5 days in vitro and subsequently declined. 3 The agonist order of potency was found to be (EC50): L‐quisqualic acid (Quis) (2 μm)»L‐glutamate (50 μm)>(1S,3R)‐11‐aminocyclopentane‐1,3‐dicarboxylic acid ((1S,3R)‐ACPD) (102 μm). L‐Glutamate (Emax = 873% of basal activity) elicited the largest stimulation of PI hydrolysis, whereas Quis (Emax = 603%) and (1S,3R)‐ACPD (Emax = 306%) produced somewhat lower stimulations. 4 Several phenylglycine derivatives were found to be active in inhibiting 2 μm Quis‐stimulated PI hydrolysis, in order of potency (IC50): (S)‐4‐carboxy‐3‐hydroxyphenylglycine (41 μm) ≤ (S)‐4‐carboxyphenylglycine (51 μm)»(+)‐α‐methyl‐4‐carboxyphenylglycine (243 μm). 5 Cultured cerebellar granule cells of the rat appear to have Group I mGluR pharmacology similar to that reported for cloned mGluRl and provide an ideal system for investigating novel mGluRl ligands in a native environment.
Biochemical Journal | 1997
Frank J. Gunn-Moore; Alan G. Williams; Nicholas J. Toms; Jeremy M. Tavaré
Neuropharmacology | 1999
Nicholas J. Toms; Peter J. Roberts
Neuropharmacology | 1999
M.E. Reid; Nicholas J. Toms; Jennifer S. Bedingfield; Peter J. Roberts
Trends in Pharmacological Sciences | 1996
Nicholas J. Toms; Peter J. Roberts; T.E. Salt; Penelope C. Staton
European Journal of Pharmacology | 1996
Jennifer S. Bedingfield; David E. Jane; Martyn C. Kemp; Nicholas J. Toms; Peter J. Roberts
European Journal of Pharmacology | 1994
Nicholas J. Toms; Peter J. Roberts
Neuropharmacology | 1997
Nicholas J. Toms; L.M. Hawkins; Peter J. Roberts